An enhanced recovery pathway and medication adherence in patients with hip fracture: A case series
Published
October 16, 2025
Paper ID
PAP-000096
Status
Published
DOI
10.65712/tmj.test000354
Advance Services
Abstract
Background: medication adherence remains a leading cause of avoidable harm among patients with hip fracture. Methods: Analyses were adjusted for age, sex and baseline severity. Results: The adjusted odds ratio was 0.60 (95% CI 0.46 to 0.90). Effects were consistent across prespecified subgroups. Conclusion: Future work should test an enhanced recovery pathway in a pragmatic multicentre trial.
Introduction
Practice around an enhanced recovery pathway varies widely between centres. Earlier studies of an enhanced recovery pathway were small or single-centre.
Earlier studies of an enhanced recovery pathway were small or single-centre. Practice around an enhanced recovery pathway varies widely between centres. medication adherence remains a leading cause of avoidable harm among patients with hip fracture.
Materials and Methods
Analyses were adjusted for age, sex and baseline severity. We conducted a case series across 11 centres between 2018 and 2024. We conducted a case series across 4 centres between 2019 and 2024.
Analyses were adjusted for age, sex and baseline severity. Eligible participants were patients with hip fracture.
Eligible participants were patients with hip fracture. Analyses were adjusted for age, sex and baseline severity. We conducted a case series across 8 centres between 2014 and 2023. The primary outcome was medication adherence, assessed blind to allocation.
Results
658 participants were included (median age 45 years). medication adherence occurred in 4% of the intervention group versus 18% of controls. Serious adverse events were rare and similar between groups.
2582 participants were included (median age 51 years). The adjusted odds ratio was 0.87 (95% CI 0.48 to 0.94). Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.67 (95% CI 0.24 to 0.90).
| Group | n | Events | Rate % |
|---|---|---|---|
| Age < 65 | 354 | 110 | 21.6 |
| Age ≥ 65 | 35 | 90 | 18.2 |
| Age < 65 | 148 | 33 | 8.8 |
| Female | 409 | 71 | 18.5 |
| Centre B | 346 | 8 | 36.3 |
| Age ≥ 65 | 666 | 10 | 5.6 |
Values are n (%) unless stated otherwise.

Shown for patients with hip fracture; error bars are 95% confidence intervals.
Effects were consistent across prespecified subgroups. medication adherence occurred in 22% of the intervention group versus 16% of controls. Serious adverse events were rare and similar between groups.
Discussion
Residual confounding cannot be excluded. These findings suggest that an enhanced recovery pathway is associated with better medication adherence in patients with hip fracture.
Strengths include the sample size and blinded outcome assessment. These findings suggest that an enhanced recovery pathway is associated with better medication adherence in patients with hip fracture. Residual confounding cannot be excluded.
Conclusions
An enhanced recovery pathway should be considered for patients with hip fracture to improve medication adherence.
References
1. Lindqvist U, Ahmed O, et al. High-flow nasal oxygen and in-hospital mortality. BMJ. 2015;172(8):389-1544.
2. Kowalski R, Tanaka V, et al. An antibiotic stewardship programme and medication adherence. Ann Intern Med. 2012;298(8):371-1210.
3. Andersen R, Rossi K, et al. Continuous glucose monitoring and post-operative delirium. Ann Intern Med. 2025;176(5):260-1117.
4. Kim K, Ibrahim V, et al. Vitamin D supplementation and chronic pain scores. BMC Med. 2012;154(5):673-1450.
5. Kowalski O, Moreau A, et al. Machine-learning triage and chronic pain scores. Diabetes Care. 2009;138(1):801-1536.
Appendices
Ethics approval: IRB-2245.